S 3304

News alerts, weekly reports and conference planners

Company:

Shionogi

Drug class:

MMP inhibitor

Related drugs:

‹

YIV-906 (0)

›

almost3years

Identification of key genes in colorectal cancer diagnosis by co-expression analysis weighted gene co-expression network analysis. (PubMed, Comput Biol Med)

Taken together, the results of the current study indicated that seven hub genes including COL1A2, COL5A1, COL5A2, SERPINH1, MMP9, SPARC, and COL1A1 which were upregulated in CRC could be used as a diagnostic and progression biomarker of CRC. On the other hand, miR-940 which targets SERPINH1 could be used as a potential biomarker of CRC. More ever, Andecaliximab, Carboxylated glucosamine, Marimastat, Tozuleristide, S-3304, Incyclinide, Curcumin, Prinomastat, Demethylwedelolactone, Bevacizumab, Ocriplasmin , and Collagenase clostridium histolyticum were introduced as therapeutic agents for CRC which their therapeutic potential should be evaluated experimentally.

almost 3 years ago

Journal

SERPINH1 (Serpin family H member 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • COL5A1 (Collagen Type V Alpha 1 Chain) • COL5A2 (Collagen Type V Alpha 2 Chain)

Avastin (bevacizumab) • S 3304 • andecaliximab (GS-5745)

3years

miR-6742-5p regulates the invasion and migration of lung adenocarcinoma cells via mediating FGF8/ERK12/MMP9/MMP2 signaling pathway. (PubMed, Aging (Albany NY))

We conclude that miR-6742-5p might be a regulator of LUAD progression by targeting FGF8/ERK1/2/MMPs signaling pathway, which provides a novel therapeutic target for LUAD.

3 years ago

Journal

MAPK1 (Mitogen-activated protein kinase 1) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)

S 3304